Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company, has secured two product patents from the Japanese Patent Office (JPO) for two of its new chemical entities (NCEs), indicated for the treatment of disorders associated with the central nervous system (CNS).
These new patents are valid till 2022. Sunven had received its first product patent granted in Japan in April this year, which is valid till 2023.
According to the invention patent disclosure, the compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder, Huntingson's disease, Parkinson and schizophrenia.
These granted patents are achieved through the internal drug discovery research efforts of Suven. Products out of these inventions may be out-licensed at the stage of clinical Phase-I or Phase-II, the company said in a press release on Thursday.
"We are pleased by the grant of these patents to Suven by JPO for our pipeline of molecules in the CNS arena that are being developed for cognitive disorders, which has an estimated $20-billion market potential globally," said Suven chief executive Venkat Jasti.
Suven Life's scrip is currently trading at Rs 29.90 on the BSE, up 4.91 per cent, over the previous close of Rs 28.50.